Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.1K

[Luminal advance breast cancer: Toward personalized medicine?]

Leah Mailly-Giacchetti1, Benjamin Verret2

  • 1Service d'oncologie médicale, Hôpital Saint-Louis, AP-HP, Paris, France.

Bulletin Du Cancer
|June 20, 2025
PubMed

Insights

The past decade saw new drugs for hormone receptor-positive, HER2-negative metastatic breast cancer, raising strategic questions. This review covers targeted therapies for advanced luminal breast cancer and future personalized treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Context:

  • Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer represents a significant clinical challenge.
  • The last decade has witnessed the emergence of novel targeted therapies, revolutionizing treatment paradigms.
  • Significant strategic questions arise regarding the optimal sequencing and combination of these agents.

Purpose:

  • To provide a comprehensive review of the current state-of-the-art targeted therapies for advanced luminal breast cancer.
  • To explore the evolving treatment strategies in HR+/HER2- metastatic breast cancer.
  • To discuss the future trajectory towards increasingly personalized treatment approaches.

Summary:

  • Review of targeted therapy advancements for HR+/HER2- metastatic breast cancer.
  • Analysis of current treatment strategies and their limitations.
  • Exploration of emerging therapeutic targets and predictive biomarkers.
  • Discussion on the integration of genomic data for personalized treatment selection.

Impact:

  • Informs clinical decision-making for oncologists treating advanced luminal breast cancer.
  • Highlights the potential for improved patient outcomes through personalized medicine.
  • Guides future research and drug development in HR+/HER2- metastatic breast cancer.
  • Facilitates a deeper understanding of the evolving landscape of breast cancer therapy.
Keywords:
Biologie moléculaireCancer du sein métastatiqueMetastatic breast cancerMolecular biologyMédecine personnaliséePersonalized medicineTargeted therapyThérapies ciblées

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.8K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K